SASSARI, Italy & PRINCETON, N.J.--(BUSINESS WIRE)--ViroStatics, a private Italian/American biopharmaceutical company developing novel therapeutics for viral and other chronic diseases, announced that a review of the first human clinical trial to test a new class of anti-HIV medications known as AntiViral-HyperActivation Limiting Therapeutics (AV-HALTs) has been published in the peer-reviewed journal PLoS ONE. The Phase 2a study demonstrated that markers of immune system hyperactivation driving HIV disease progression can be rapidly and effectively reduced by AV-HALTs, resulting in a proportional restoration of immune system damage. “It has been more than thirty years since the first AIDS cases were reported,” said Franco Lori, MD and CEO of ViroStatics. “Since these first reports, the field has made great advances against HIV. Yet, an unmet medical need remains – how to directly reduce the immune system’s excessive response to the virus, a response that paradoxically becomes harmful over time.”
